{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"7.4","value":"4.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Progression free survival defined as the time from the first day of transarterial chemoperfusion treatment to disease progression based on imaging findings using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m\\^2), methotrexate (100 mg/m\\^2) and gemcitabine (1000 mg/m\\^2).\n\nPatients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.\n\nQuality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.\n\nCisplatin: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.\n\nMethotrexate: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\\^2).\n\nGemcitabine: The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.\n\nLung Cancer Symptom Scale for Mesothelioma Questionnaire: Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.","id":"OG000","title":"Chemoperfusion + Questionnaire"}],"paramType":"MEDIAN","populationDescription":"All evaluable participants. Study patients cannot be analyzed separately. No dose limiting toxicities observed, therefore all participants received same dosing.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}